Abstract
Patients aged ≤50 years are rarely diagnosed with nonsmall cell lung cancer. We conducted a retrospective cohort study to understand the mutation status of EGFR and the efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in young Asian patients with lung adenocarcinoma.
We collected tumour specimens and malignant pleural effusions from lung adenocarcinoma patients from June 2005 to April 2014, recorded their clinical demographic data, and analysed EGFR mutations by reverse transcriptase PCR.
EGFR mutation data were collected from 1039 lung adenocarcinoma patients, including 161 patients aged ≤50 years and 878 patients aged >50 years. Fewer patients aged ≤50 years had EGFR mutations than older patients (p=0.043), but they showed a higher rate of uncommon EGFR mutations (p=0.035). A total of 524 patients with EGFR mutations received EGFR-TKI treatment, including 81 patients aged ≤50 years. Younger patients had a lower response rate than older patients (p=0.038) and had the shortest progression-free survival compared with other predefined age categories (p=0.033). Multivariate analysis of overall survival revealed age ≤50 years as a poor prognostic factor.
In conclusion, fewer Asian patients aged ≤50 years had EGFR mutations, but the EGFR mutation types were more uncommon. Age ≤50 years is associated with poorer efficacy of EGFR-TKI treatment.
Abstract
Association between age and EGFR mutations http://ow.ly/jV4n30bRBUX
Footnotes
This article has supplementary material available from openres.ersjournals.com
Support statement: This study was supported by grants NSC101-2314-B-002-167-MY3 and MOST104-2314-B-002-172-MY3 (Ministry of Science and Technology, ROC), MOHW103-TDU-PB-211-144002 (Ministry of Health and Welfare), NHRI-EX104-10421BI and NHRI-EX105-10421BI (National Health Research Institutes), NTU104-FTN09 and NTU105-S3032 (National Taiwan University, Taiwan), and NTUHYL104.M001 and NTUHYL105.X004 (National Taiwan University Yun-Lin Branch, Yun-Lin, Taiwan). Funding information for this article has been deposited with the Crossref Funder Registry.
Conflict of interest: Disclosures can be found alongside this article at openres.ersjournals.com
- Received August 17, 2016.
- Accepted May 8, 2017.
- Copyright ©ERS 2017
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.